WHOã¯ã¤ã³ãã«ã¨ã³ã¶ã¯ã¯ãã³æ¥ç¨®ãæ¨å¥¨ãã¦ãã
2015.3.16追è¨
ç¶å ±ãæ¸ãã¾ããã
2015.1.26追è¨
å
è¨äºã¯ç¾å¨ã1æ23æ¥ã«æ²è¼è´ãã¾ããæ¬ä»¶è¨äºã«ã¤ãã¾ãã¦ãç¾å¨è¿½å åæä¸ã«ã¤ãä¸æçã«éå
¬éã«ãã¦ããã¾ããã¨è¨è¼ããå
¬éåæ¢ããã¦ãã¾ããããããªããããã£ããæ¡æ£ããã誤æ
å ±ã¯è»¢è¼çã«ãããããä¸ã§ãªãã©ããã¿ããããå©ç¨ããããã¨ãããã¾ãããã®è¨äºã¯ãã®ãããªã¨ãã®ããã«ã¨ããããã¯æ¶ãã¾ãããBusiness Journal ã«ããé©åãªè¨æ£ããªããããã¨ãé¡ãã¾ãã
ã¤ã³ãã«ã¨ã³ã¶ã®æµè¡ããã¼ã¯ãè¿ãã¦ãã¾ãããããªä¸ãä¸è¨ã®ãããªè¨äºãå ¬éããã¾ããã
- WHO、インフルエンザはワクチンで予防不可と結論 病院は巨額利益、接種しても感染多数, Business Journal, 2015.01.23ï¼éæï¼
ãã®è¨äºã«ã¯ãä¸çä¿å¥æ©é¢ï¼WHOï¼ã®ãã¼ã ãã¼ã¸ãè¦ã¦ãããã¯ã¯ãã³ã§ãã¤ã³ãã«ã¨ã³ã¶ææã®äºé²ã¯ã§ããªããã¾ãæå¹ã¨ãããã¼ã¿ããªããã¨æ¸ãã¦ããã¾ãããããããã¤ã³ãã«ã¨ã³ã¶ã¯Aé¦æ¸¯åãAã½é£åãBåãªã©ã¨åé¡ãã¾ãããåãåã§ãã£ã¦ãã¦ã¤ã«ã¹ã¯ç´°ããå¤ç°ãç¶ãã¦ãããããã´ã£ããã¨å½ã¦ã¯ã¾ãåã®ã¦ã¤ã«ã¹ãäºåã«ã¤ããåºããã¨ã¯äºå®ä¸ä¸å¯è½ã§ãããªã©ã®è¨è¿°ãããããã¯ã¯ãã³ãæã¤ãã¨ã®æ¯éã¯æè¦ãåãããã¨ããã ããäºé²å¹æã«ã¯å¤å°çåããããããã©ããããæ¯å¹´ã¯ã¯ãã³ã®å¯ä½ç¨ã«ãã£ã¦æ»è ãåºã¦ãããæ°æ§ã§æ¥ç¨®ããã®ã§ã¯ãªããçæ ®ã®ä¸ã§å¤æãããããå§ããããããã¨çµãã§ãã¾ãããçæ ®ã®ä¸ãã¨è¨ããã¦ãç´ äººã«ã¯å¤æãé常ã«é£ãããã¨ã§ããããã®WHOããææäºé²ã¯ã§ããªããã¨çµè«ãããªãããããªãã»ããããããªâ¦ãªãã¦æã£ã¡ããããã§ãã
ã§ã¯ãWHOã®ã¤ã³ãã«ã¨ã³ã¶ã«é¢ããWebãã¼ã¸ã§ã¯ã©ãæ¸ããã¦ããã®ã§ããããããã¡ã¯ãã·ã¼ãã®ãäºé²ãã®é ç®ããã£ã¨è¨³ãã¦ã¿ã¾ããï¼ãªããä»åã®è¨³ã¯ããã¾ã§ãã£ããã§ãã®ã§ãç´°ããå»å¦ç¨èªã«ééããããããããã¾ãããããã¾ã§åèã«ã¨ã©ãã¦ãã ããã¾ãããããããããã¾ãï¼ã
- Influenza (Seasonal), Fact sheet N°211, March 2014
äºé²
ã¤ã³ãã«ã¨ã³ã¶ããã³/ã¾ãã¯ããã«ããé篤ãªè»¢å¸°ãé²ãã®ã«ãã£ã¨ãæå¹ãªæ段ã¯äºé²æ¥ç¨®ã§ãããå®å ¨ã§æå¹ãªã¯ã¯ãã³ãå©ç¨å¯è½ã§ããã60年以ä¸åãã使ç¨ããã¦ãããæ£å¸¸æ人ã«å¯¾ãã¦ã¯ãã¤ã³ãã«ã¨ã³ã¶ã¯ã¯ãã³ã¯å¦¥å½ãªé²å¾¡æ段ã¨ãªãã ãããé«é½¢è ã«å¯¾ãã¦ã¯ãã¤ã³ãã«ã¨ã³ã¶ã¯ã¯ãã³ã®ç¾ç äºé²å¹æã¯ä½ããªãå¯è½æ§ãããããéç度ããåä½µççºççããã³æ»äº¡çãä½ä¸ããããããããªãã
äºé²æ¥ç¨®ã¯ãéçã¤ã³ãã«ã¨ã³ã¶åä½µçã«å¯¾ãã¦æ¯è¼çãã¤ãªã¹ã¯ãªäººãã¾ããã¤ãªã¹ã¯ãªäººã¨çæ´»ãå ±ã«ãã¦ãã人ãä»è·ãã¦ãã人ã«ã¯ãç¹ã«éè¦ã§ããã
WHOã¯ä»¥ä¸ã®äººã«å¯¾ãã¦æ¯å¹´äºé²æ¥ç¨®ãããã¨ãæ¨å¥¨ããã
- å¦å¨ ã®ãã¹ã¦ã®æ®µéã«ããå¦å©¦
- çå¾6ã¶æã5æ³ã®åã©ã
- é«é½¢è ï¼65æ³ä»¥ä¸ï¼
- æ ¢æ§ç¾æ£ã®ãã人
- å»çå¾äºè
ã¤ã³ãã«ã¨ã³ã¶äºé²æ¥ç¨®ã¯ãåºã¾ã£ã¦ããã¦ã¤ã«ã¹ãã¯ã¯ãã³ã¨ããä¸è´ãã¦ããå ´åã«ãã£ã¨ãæå¹ã§ãããã¤ã³ãã«ã¨ã³ã¶ã¦ã¤ã«ã¹ã¯çµ¶ããå¤åãããããWHO Global Influenza Surveillance and Response System (GISRS)ï¼ä¸çåå°ã®National Influenza Centresãé£æºãã¦ããï¼ããããã®éã§å¾ªç°ãã¦ããã¤ã³ãã«ã¨ã³ã¶ã¦ã¤ã«ã¹ãç£è¦ãã¦ããã
WHOã¯é·å¹´ãã¯ã¯ãã³ã®æåã«ã¤ãã¦ã®æ¨å¥¨ãåå¹´ãã¨ã«æ´æ°ãã¦ãããããã¯ããã£ã¨ãåºã¾ã£ã¦ãã3ã¤ã®ã¦ã¤ã«ã¹ã®åï¼3価/2種é¡ã®Aåã¦ã¤ã«ã¹ã¨1種é¡ã®Båã¦ã¤ã«ã¹ï¼ã対象ã¨ãã¦ããã2013-2014ã®ååçã®ã¤ã³ãã«ã¨ã³ã¶ã·ã¼ãºã³ã®å§ã¾ãã¨å ±ã«ãå¾æ¥ã®3価ã¯ã¯ãã³ã«å ããBåã¦ã¤ã«ã¹ã®ç¬¬2ã®åãå ãã4価ã¯ã¯ãã³ã®æåã«ã¤ãã¦ãæ¨å¥¨ãéå§ãã¦ããã4価ã®ã¤ã³ãã«ã¨ã³ã¶ã¯ã¯ãã³ã¯ãBåã¤ã³ãã«ã¨ã³ã¶ã¦ã¤ã«ã¹ã®ææã«å¯¾ãã¦ãããå¹ åºãé²å¾¡å¹æãæå¾ ãããã
Prevention
The most effective way to prevent the disease and/or severe outcomes from the illness is vaccination. Safe and effective vaccines are available and have been used for more than 60 years. Among healthy adults, influenza vaccine can provide reasonable protection. However among the elderly, influenza vaccine may be less effective in preventing illness but may reduce severity of disease and incidence of complications and deaths.Vaccination is especially important for people at higher risk of serious influenza complications, and for people who live with or care for high risk individuals.
WHO recommends annual vaccination for:
- pregnant women at any stage of pregnancy
- children aged 6 months to 5 years
- elderly individuals (≥65 years of age)
- individuals with chronic medical conditions
- health-care workers.
Influenza vaccination is most effective when circulating viruses are well-matched with vaccine viruses. Influenza viruses are constantly changing, and the WHO Global Influenza Surveillance and Response System (GISRS) – a partnership of National Influenza Centres around the world –monitors the influenza viruses circulating in humans.
For many years WHO has updated its recommendation on vaccine composition biannually that targets the 3 (trivalent) most representative virus types in circulation (two subtypes of influenza A viruses and one B virus). Starting with the 2013-2014 northern hemisphere influenza season, quadrivalent vaccine composition has been recommended with a second influenza B virus in addition to the viruses in the conventional trivalent vaccines. Quadrivalent influenza vaccines are expected to provide wider protection against influenza B virus infections.
以ä¸ã®ããã«WHOã¯ã¯ã£ããã¨ã¤ã³ãã«ã¨ã³ã¶ã¯ã¯ãã³æ¥ç¨®ãæ¨å¥¨ãã¦ãã¾ãããããããæä¸ã«ããããã«ãWHOèªèº«ããã¯ã¯ãã³ã«ä½¿ç¨ãã¹ãæ ªã®æ¨å¥¨ãçºè¡¨ãã¦ããã®ã§ãã
âãã¡ããããã¯ã¯ãã³ã«ä½¿ç¨ããæ ªã®ãªã³ã¡ã³ãã¼ã·ã§ã³ãè¦ããã¨ãã§ãã¾ããååçã¨ååçã§å¥ã«ãªã£ã¦ãã¾ããã
âã¾ãããã®ãããªãã£ã³ãã¼ã³ãããã¾ãã
Global Action Plan for Influenza Vaccines (GAP)ã¯ãä¸çåå½ã«ããã¦ãå£ç¯æ§ã®ã¨ããããã¯ããã³ãã³ãããã¯ã«å¯¾ããç¾å¨ã®ä¸ççãªã¤ã³ãã«ã¨ã³ã¶ã¯ã¯ãã³ä¸è¶³ãæ¹åããããã®å æ¬çæ¦ç¥ã§ããã以ä¸ã®3ã¤ã主è¦ãªåãçµã¿ã¨ããã
- ã·ã¼ãºã³ãã¨ã®ã¯ã¯ãã³ä½¿ç¨ãå¢å ãããã
- ã¯ã¯ãã³è£½é è½åãæ¡å¤§ããã
- ç 究éçº
Global Action Plan for Influenza Vaccines (GAP) is a comprehensive strategy to reduce the present global shortage of influenza vaccines for seasonal epidemics and pandemic influenza in all countries of the world through three major approaches:
- Increase in seasonal vaccine use
- Increase in vaccine production capacity
- Research and development
å è¨äºã§ã¯ãææäºé²å¹æãã«ã®ã¿ãã©ã¼ã«ã¹ãã¦ãã¾ãããWHOã®ãµã¤ãã«ããããã«ãéçåãåä½µçã®äºé²ãæ»äº¡çãä½ä¸ãããããã¨ã«ã大ããªæå³ã¯ããã¾ããWHOã®ãçµè«ãã¯ããã¯ã¯ãã³ã§ã¤ã³ãã«ã¨ã³ã¶ã¯ææäºé²ä¸å¯è½ãã§ã¯ãªãããå¦å©¦ãé«é½¢è ãåã©ããæ ¢æ§ç¾æ£ã®ãã人ãå»çå¾äºè ã¯æ¯å¹´äºé²æ¥ç¨®ãããã¨ãå§ãããã§ããæ¯åæ¸ãã¦ãã¾ããããããä¸ã®ã¯ã¯ãã³æ å ±ã¯ãã¤ãºãããªãå¤ãã§ãã®ã§ãäºé²æ¥ç¨®ã«ã¤ãã¦è¿·ã£ããããããã¤ãã®ãå»è ããã«ç¸è«ãããã¨ããããããã¾ãã